Entering text into the input field will update the search result below

Pluristem inks agreement with DoD to study PLX-R18 in mustard gas exposure; shares down 2% premarket

Jun. 19, 2018 7:45 AM ETPluri Inc. (PLUR) StockBy: Douglas W. House, SA News Editor5 Comments
  • Pluristem Therapeutics (NASDAQ:PSTI) will collaborate with the U.S. Department of Defense to study its PLX-R18 cell therapy product for the treatment long-term lung injuries following exposure to mustard gas.
  • The agreement is the second DoD  study involving PLX-R18. The first is evaluating its use as a countermeasure for acute radiation syndrome.
  • Financial terms are not disclosed.
  • Shares are down 2% premarket on increased volume.

Recommended For You

About PLUR Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PLUR--
Pluri Inc.